ArticleBMC pediatrics2026
Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundShort bowel syndrome (SBS) imposes a substantial burden on pediatric patients and their caregivers. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, promotes intestinal adaptation by enhancing villus hyperplasia and crypt deepening. This study aimed to evaluate its impact on the health-related quality of life (HRQoL) of children with SBS and their caregivers.
methodsIn this matched case-control study, 24 children with SBS were enrolled (8 received teduglutide, 16 served as controls). Child HRQoL was assessed using the PedsQL™ Infant Scales and 4.0 Generic Core Module; caregiver HRQoL was evaluated with the PedsQL™ 3.0 Family Impact Module. HRQoL scores were compared between groups using independent t-tests and within the teduglutide group (pre- vs. post-treatment) using paired t-tests.
resultsBaseline characteristics were comparable between groups (p > 0.05). The teduglutide group had a significantly shorter residual intestinal length (43.3 vs. 62.1 cm, P = 0.022). Treatment reduced parenteral nutrition (PN) calorie intake from 53.13 to 28.12 kcal/kg/day (P = 0.036). Teduglutide significantly improved children's total HRQoL (63.88 to 71.89, P = 0.046) and psychosocial scores (68.18 to 75.34, P = 0.027), reaching levels comparable to controls (73.53, P = 0.806; 75.84, P = 0.946, respectively). Caregivers' HRQoL also increased significantly (57.55 to 68.32, P = 0.049), surpassing that of the control group (56.80, P = 0.298).
conclusionsTeduglutide significantly enhances HRQoL in children with SBS and their caregivers, potentially through intestinal rehabilitation and reduced PN dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.